11. The compound according to claims 1-8 wherein R_5 is C(6)arylC(1-3)alkyl or C(3-6)cycloalkylC(1-3)alkyl.

12. The compound according to claim 11 wherein R_5 is benzyl.

13. The compound according to claims 1-12 wherein R_6-R_{10} are H with the proviso that one of the groups R_7, R_8 or R_9 is the sulfonyl group with R_1.

14. The compound according to claim 13 wherein R_8 is the sulfonyl group with R_1.

15. The compound according to claims 1-12 wherein R_8 is the sulfonyl group with R_1, and wherein R_{10} is methyl, and the remaining R_6, R_7 and R_9 are H.

16. The compound according to claims 1-15 wherein A_{11}-A_{14} are CR_{11}, CR_{12}, CR_{13} and CR_{14}, respectively.

17. The compound according to claims 1-15 wherein either:
A_{11} is nitrogen and A_{12}-A_{14} are CR_{12}, CR_{13} and CR_{14}, respectively; or,
A_{12} is nitrogen and A_{11}, A_{13} and A_{14} are CR_{11}, CR_{13} and CR_{14}, respectively.

18. The compound according to claims 1-17 wherein R_{11}-R_{14} are independently H, halogen, methyl or methoxy.

19. The compound according to claim 18 wherein R_{11}-R_{14} is H.

20. The compound according to claims 1-19 wherein R_{15} is CF_3 and R_{16} is H, C(1-6)alkyl, C(3-6)cycloalkyl or C(3-6)cycloalkylC(1-3)alkyl.

21. The compound according to claims 1-19 wherein R_{15} is CF_3 and R_{16} is CF_3, propyl, isopropyl, 2-methylpropyl, 2,2-dimethylpropyl, cyclopropyl, cyclopentyl or cyclohexylmethyl.

22. The compound according to claim 21 wherein both R_{15} and R_{16} are CF_3.

23. The compound selected from claim 1 which is selected from the group of:

N-(4-(2-butoxy-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl)-2-(4-((cyclopropylmethyl)sulfonyl)phenyl)acetamide;

2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(4-(2-ethoxy-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl)acetamide;

2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(4-(1,1,1,3,3,3-hexafluoro-2-methoxypropan-2-yl)phenyl)acetamide;

2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-methoxyphenyl)acetamide;

2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-3-methoxyphenyl)acetamide;

N-(4-(2-(2-cyclopropylethoxy)-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl)-2-(4-((cyclopropylmethyl)sulfonyl)phenyl)acetamide;

N-(4-(2-(benzyloxy)-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl)-2-(4-((cyclopropylmethyl)sulfonyl)phenyl)acetamide;

2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(4-(1,1,1,3,3,3-hexafluoro-2-propoxypropan-2-yl)phenyl)acetamide;

2-(4-(*N*-cyclopropylsulfamoyl)phenyl)-*N*-(4-(1,1,1,3,3,3-hexafluoro-2-propoxypropan-2-yl)phenyl)acetamide;

N-(3-chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-2-(4-((cyclopropylmethyl)sulfonyl)phenyl)acetamide;

2-(4-(ethylsulfonyl)phenyl)-*N*-(4-(1,1,1-trifluoro-2-hydroxypentan-2-yl)phenyl)acetamide;

2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-*N*-(4-(1,1,1-trifluoro-2-hydroxyhexan-2-yl)phenyl)acetamide;

2-(4-(ethylsulfonyl)phenyl)-*N*-(4-(1,1,1-trifluoro-2-hydroxy-3-methylbutan-2-yl)phenyl)acetamide;


2-(4-(ethylsulfonyl)phenyl)-*N*-(4-(1,1,1-trifluoro-2-hydroxy-4-methylpentan-2-yl)phenyl)acetamide;

N-(4-(1-cyclopropyl-2,2,2-trifluoro-1-hydroxyethyl)phenyl)-2-(4-((cyclopropylmethyl)sulfonyl)phenyl)acetamide;

N-(4-(3-cyclopentyl-1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)-2-(4-((cyclopropylmethyl)sulfonyl)phenyl)acetamide;

28. A pharmaceutical composition according to claim 27, which further comprises at least one additional therapeutically active agent.

29. A compound according to Formula **I**



Meta or para

(Formula **I**)

or a pharmaceutically acceptable salt thereof wherein

A_{11} – A_{14} are N or CR_{11}, CR_{12}, CR_{13}, CR_{14}, respectively, with the proviso that no more than two of the four positions A can be simultaneously N;

R_1 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(1-6)alkylamino, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino, with all carbon atoms of alkyl groups optionally substituted with one or more F and all carbon atoms of cycloalkyl groups optionally substituted with one or more F or methyl;

R_2 and R_3 are independently H, F, methyl, ethyl, hydroxy, methoxy or R_2 and R_3 together is carbonyl, all alkyl groups, if present, optionally being substituted with one or more F;

R_4 is H or C(1-6)alkyl;

R_5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with one or

more F, Cl, C(1-2)alkyl, C(1-2)alkoxy or cyano ;

the sulfonyl group with R_1 is represented by one of R_7, R_8 or R_9;

the remaining R_6-R_{14} are independently H, halogen, C(1-3)alkoxy, (di)C(1-3)alkylamino or C(1-6)alkyl, all of the alkyl groups optionally being substituted with one or more F;

R_{15} and R_{16} are independently H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with one or more F, Cl, C(1-2)alkyl, C(1-2)alkoxy or cyano; and

wherein (di)C(1-6)alkylamino is an amino group, which is monosubstituted or disubstituted independently with H or C(1-6)alkyl groups.

30. The compound according to claim 29 which is *N*-(2-amino-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-2-(4-((cyclopropylmethyl)sulfonyl)phenyl)acetamide.